An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder

NCT00332891 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
508
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi